Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC

(AGN)
My previous session
Most popular
  Report  
Delayed Quote. Delayed Nyse - 03/22 04:00:29 pm
149.3 USD   -2.76%
03/22ALLERGAN : promises independent board chair in next leadership change
RE
03/22ALLERGAN : 2018 Form 10-K (PDF)
PU
03/21ALLERGAN : Amendment to a previously filed 4
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Allergan : Notice of exempt solicitation. Definitive material

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/04/2019 | 12:20pm EDT

U.S. Securities and Exchange Commission

Washington, DC 20549

Notice of Exempt Solicitation

Amendment No. 2

NAME OF REGISTRANT: Allergan plc

NAME OF PERSON RELYING ON EXEMPTION: Appaloosa LP

ADDRESS OF PERSON RELYING ON EXEMPTION: 51 John F. Kennedy Parkway, Short Hills, New Jersey 07078 WRITTEN MATERIALS: The following written materials are attached:

Exhibit 1: Press Release regarding letter from Appaloosa LP to Allergan plc's Board of Directors, dated February 5, 2019 (previously filed) Exhibit 2: Press Release regarding letter from Appaloosa LP to Allergan plc's Board of Directors, dated February 19, 2019 (previously filed) Exhibit 3: Press Release regarding John Chevedden's support of Appaloosa LP's proposal, dated February 28, 2019

Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. Submission is not required of this filer under the terms of the Rule, but is made voluntarily in the interest of public disclosure and consideration of these important issues.

ALLERGAN SHAREHOLDER AND CORPORATE GOVERNANCE ADVOCATE TO

SUPPORT APPALOOSA PROPOSAL

NEW YORK - February 28, 2019 - Appaloosa LP and John Chevedden announced today that, following discussions between Appaloosa and Mr. Chevedden regarding their respective shareholder proposals calling for Allergan plc to separate the roles of Chairman and Chief Executive Officer, Mr. Chevedden has determined to withdraw his proposal and support Appaloosa's proposal.

Mr. Chevedden said, "The Appaloosa proposal is the better proposal for Allergan shareholders because it contemplates immediate implementation upon approval by shareholders."

David Tepper, President of Appaloosa, said, "John Chevedden has worked tirelessly for many years to advance important corporate governance initiatives and we are gratified that he shares our view regarding the need for an immediate separation of the Chairman and CEO roles at Allergan. Mr. Chevedden's decision to withdraw his proposal will eliminate unnecessary confusion, enabling shareholders to focus on effecting meaningful changes to the leadership structure at Allergan as a first step to arresting the company's decline."

Mr. Chevedden noted that his proposals on this same topic won more than 42% of the for and against votes at both the Allergan 2016 and 2018 annual general meetings. These meetings were held in Ireland by Allergan, which Mr. Chevedden believes discouraged shareholder participation.

Media Contacts

Jonathan Gasthalter/Nathaniel Garnick Gasthalter & Co.

(212) 257-4170

IMPORTANT NOTICE

Funds advised by Appaloosa LP ("Appaloosa") have submitted to Allergan plc ("Allergan") a shareholder proposal to separate the roles of Chairman and Chief Executive Officer to be considered at Allergan's 2019 annual general meeting of shareholders. This communication is not a solicitation of proxies and Appaloosa is not seeking authority to vote any proxy in connection with Allergan's annual general meeting. Shareholders should NOT send us any proxy card. Following the dissemination of Allergan's proxy materials for the annual general meeting, shareholders will be able to vote for Appaloosa's shareholder proposal by executing and returning the form of proxy card furnished by Allergan in accordance with the procedures set forth in Allergan's proxy materials. Shareholders with questions may contact Okapi Partners, Appaloosa's Information Agent, toll free in the U.S. and Canada at (877) 869-0171 or at +1 (212) 297-0720 outside of the U.S. or Canada.

Disclaimer

Allergan plc published this content on 04 March 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 04 March 2019 16:19:03 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN PLC
03/22ALLERGAN : promises independent board chair in next leadership change
RE
03/22ALLERGAN PLC : Other Events (form 8-K)
AQ
03/22ALLERGAN : 2018 Form 10-K (PDF)
PU
03/22ALLERGAN : Announces FDA Approval of AVYCAZ for Pediatric Patients
AQ
03/21ALLERGAN : Amendment to a previously filed 4
PU
03/21ALLERGAN : CoolSculpting® and Sonja Morgan Talk Bikini Denial Just In Time For S..
PR
03/21ALLERGAN : CoolSculpting and Sonja Morgan Partner to Talk Bikini Denial
AQ
03/20ALLERGAN : CoolSculpting® and Sonja Morgan Partner to Talk Bikini Denial
PR
03/19ALLERGAN : Announces FDA Approval of AVYCAZ for Pediatric Patients
AQ
03/18ALLERGAN : Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Ped..
PR
More news
Financials ($)
Sales 2019 15 173 M
EBIT 2019 7 079 M
Net income 2019 288 M
Debt 2019 18 084 M
Yield 2019 1,99%
P/E ratio 2019 259,92
P/E ratio 2020 28,70
EV / Sales 2019 4,46x
EV / Sales 2020 4,06x
Capitalization 49 659 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 184 $
Spread / Average Target 23%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Charles Hugh-Jones Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC11.70%49 659
JOHNSON & JOHNSON6.09%364 560
NOVARTIS10.71%239 248
ROCHE HOLDING LTD.10.68%233 745
PFIZER-4.12%232 343
MERCK AND COMPANY7.70%212 409